What question did this study set out to answer?

To analyze the pathophysiological mechanisms, clinical features, diagnostic criteria, and current evidence-based management strategies for chronic heart failure.

March 6, 2026Open Access

Chronic Heart Failure: Pathophysiology, Clinical Manifestations and Contemporary Management

Q: What are the key findings of this study?

Guideline-directed medical therapy combining ACE inhibitors, beta-blockers, MRAs, and SGLT2 inhibitors significantly reduces mortality and hospitalization rates in adults with chronic heart failure.

Q: What is the clinical evidence from this study?

Study design: Review. Population: Adults (≥18 years) with diagnosed chronic heart failure. Intervention: Guideline-directed medical therapy (combination ACE inhibitors, beta-blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors) vs. Placebo or standard care without combination therapy. Primary outcome: Mortality and hospitalization rates.

Q: What does this research mean for the field?

Guideline-directed medical therapy combining ACE inhibitors, beta-blockers, MRAs, and SGLT2 inhibitors significantly reduces mortality and hospitalization rates in adults with chronic heart failure. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Key result

Quadruple GDMT reduces mortality and hospitalization rates in chronic heart failure.

Why the study?

Chronic heart failure represents a leading cause of hospitalization and mortality worldwide, characterized by neurohormonal activation, reduced cardiac output, and systemic congestion.

Design

Review

Authors

AQAbdusamiyeva Nargiza QudratovnaMisamis University TQTangriyeva Mohinur Hazratqul qiziMohi-ud-Din Islamic University OOOdiljonov Ozodbek Odiljon o'g'liHrvatski zavod za javno zdravstvo

Discussion

Member takes

Implication

Prioritizes quadruple GDMT optimization in all chronic HF patients; confirms additive benefits of the four pillars.

Key Points

To analyze the pathophysiological mechanisms, clinical features, diagnostic criteria, and current evidence-based management strategies for chronic heart failure.
Review based on analysis of international cardiology guidelines (ESC, AHA/ACC), randomized controlled trials, and meta-analyses published between 2015–2024.
Included studies focusing on adults aged ≥18 years with diagnosed chronic heart failure and sample sizes of ≥500 participants.
Excluded acute heart failure, congenital heart disease, and pediatric cardiology cases, evaluating left ventricular ejection fraction, hospitalization, mortality, and pharmacotherapy response.
Chronic heart failure affects over 64 million individuals globally, with heart failure with reduced ejection fraction (LVEF <40%) accounting for approximately 50% of cases.
Guideline-directed medical therapy using combined pharmacological classes (ACE inhibitors, beta-blockers, MRAs, and SGLT2 inhibitors) reduces mortality and hospitalizations compared to stepwise escalation.
Disease progression is driven by a cycle of myocardial injury, neurohormonal activation via the renin-angiotensin-aldosterone and sympathetic nervous systems, and adverse cardiac remodeling.

Structured PICO

Population

Adults ≥18 years diagnosed with chronic heart failure (excluding acute heart failure, congenital heart disease, and pediatric cases) based on studies with ≥500 participants.

Intervention

Guideline-directed medical therapy (GDMT) including ACE inhibitors, beta-blockers, MRAs, SGLT2 inhibitors, and device-based interventions (ICD, CRT, LVAD, heart transplantation).

Outcome

Left Ventricular Ejection Fraction (LVEF), hospitalization rates, mortality outcomes, and response to pharmacological therapy

Early diagnosis and comprehensive pharmacological and device-based interventions significantly improve prognosis and quality of life in chronic heart failure.

Limitations

No original clinical trial data presented, only review of existing guidelines and trials.
Specific quantitative results and statistics from primary studies are not detailed.
No primary endpoint data extracted as the paper is a narrative review rather than a clinical trial.

Cite This Study

Qudratovna et al. (2026) conducted a review in Adults (≥18 years) with diagnosed chronic heart failure. Guideline-directed medical therapy (combination ACE inhibitors, beta-blockers, mineralocorticoid receptor antagonists, SGLT2 inhibitors) vs. Placebo or standard care without combination therapy was evaluated on Mortality and hospitalization rates. Guideline-directed medical therapy combining ACE inhibitors, beta-blockers, MRAs, and SGLT2 inhibitors significantly reduces mortality and hospitalization rates in adults with chronic heart failure.

synapsesocial.com/papers/69aa7066531e4c4a9ff5a364 https://doi.org/10.5281/zenodo.18861307

Topics

Heart failure Heart failure hospitalization HFrEF treatment HFpEF management

View Full Paper

Ask AI

Bookmark

Chronic Heart Failure: Pathophysiology, Clinical Manifestations and Contemporary Management

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Topics

Chronic Heart Failure: Pathophysiology, Clinical Manifestations and Contemporary Management

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider